Starting January 1, 2025, most Blue Shield commercial members using Fresenius Kabi's adalimumab-aacf (a Humira biosimilar) ...

Seven new clinical trial grants were awarded under the Orphan Product Grants Program during the fiscal year (FY) 2024, ...

A federal judge in New York has ruled that Amgen must answer to claims of misleading investors about billions owed to US tax ...

The month-long standoff between the US Health Resources and Services Administration (HRSA) and Johnson & Johnson came to an ...